ACAD

As of 2026-09-10, ACAD scores 51out of 100 on QNTM’s five-factor quantitative model, a moderate conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. ACAD trades at $27.74, 44% above the band ceiling.

ACAD scores 51 out of 100 on QNTM's five-factor model — a moderate reading — neither strongly favored nor flagged for weakness at 51. Its strongest factor is quality at 58 (solid), where earnings quality and balance-sheet strength stand out, followed by momentum at 58. The weakest is sentiment at 31, where sentiment signals are working against it. Among Healthcare stocks it ranks in roughly the top 30% of the Healthcare names the model scores.

On valuation, ACAD is priced near the top of its recent range — the rich end on the model's valuation read. The blended composite before the macro overlay was 53. Same-sector names the model rates nearby include HALO, THC, TGTX.

This is a descriptive factor read on ACAD, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where ACAD sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for ACAD runs $13.43–$19.28. Current price $27.74 sits 44% above the band ceiling. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-09-10.